PrintThe Burrill Report
The Burrill Report (April 30, 2012): Saying "No" to an IPO (.MP3,18.23 Mb)
Argos Therapeutics recently completed a $25 million financing to advance its personalized immunotherapy as a treatment for kidney cancer. The company had hoped to raise $86.3 million in an IPO, but pulled that deal last month after it decided it wasn’t willing to sell stock at prices that public market investors were willing to pay. We spoke to Jeff Abbey, CEO of Argos, about the reception biotech companies receive on Wall Street today, the difficult calculus they face in deciding whether to take what they can get or seek alternative sources of funding, and with less money than they will need to commercialize their lead product, what the path forward for Argos looks like from here.
April 27, 2012
http://www.burrillreport.com/article-saying_no_to_an_ipo.html
INITIAL PUBLIC OFFERINGS
Saying "No" to an IPO
Podcast: April 30, 2012[Please login to post comments]
- FDA’s Woodcock Argues for Clinical Research Makeover
Academia can and should play a greater role in bringing better drugs to market, says CDER director. Read More - FDA Stretches to Go Global
With limited resources, agency targets trouble spots and seeks cooperation. Read More - AstraZeneca Agrees to Buy Ardea Biosciences for $1.3 Billion
Similar acquisitions are likely as AstraZeneca tries to replenish its pipeline. Read More - NIH grants $10.5 Million for Genome Explorations
Grants will back work to illuminate genome function. Read More - AstraZeneca CEO to Step Down
Poor R&D; productivity and heightened generic drug competition hamper company. Read More - P2P Healthcare and the Portals of Power
Pharma should embrace social media and its creative destruction. Read More - Tackling Oral Cancer with a Smartphone
For a few dollars, camera phones can catch cancers and prevent deaths. Read More - Takeda Fails to Win FDA Approval for Diabetes Drug
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More - Buyouts Catch Fire in Race for Global Market Share
April ends with $20.6 billion in M&A; against a somber outlook for life sciences IPOs. Read More - Novartis Challenging Avastin Use for Eye Disease in the U.K.
Lawsuit claims patient safety is being compromised. Read More
.gif)
